Alpha-Klotho

Alpha-Klotho (alpha-KL) is a 130 kDa type I single-pass transmembrane protein encoded by the KL gene on human chromosome 13q13.1, first identified in 1997 by Kuro-o et al. through characterization of an insertional mutation in mice that produced a syndrome of accelerated aging encompassing soft tissue calcification, arteriosclerosis, skin atrophy, osteoporosis, emphysema, gonadal dysplasia, and dramatically shortened lifespan [1]. The protein comprises a short intracellular domain, a single transmembrane helix, and a large extracellular region containing two tandem glycosyl hydrolase family 1 (GH1) domains, designated KL1 and KL2, which share sequence homology with family 1 beta-glucosidases but lack catalytic activity against conventional substrates due to substitutions in the active-site residues. The extracellular domain undergoes proteolytic shedding by ADAM10, ADAM17, and BACE1, generating a soluble ectodomain (sKL) comprising KL1 and KL2 that circulates as an endocrine factor detectable in plasma, cerebrospinal fluid, and urine. A shorter secreted isoform containing only KL1 is produced by alternative mRNA splicing.

In its membrane-bound form, alpha-Klotho functions as an obligate co-receptor for fibroblast growth factor 23 (FGF23), forming a ternary complex with FGF receptor 1c (FGFR1c) that is essential for phosphaturic signaling in the renal proximal tubule and for suppression of 1,25-dihydroxyvitamin D3 (calcitriol) synthesis. The crystal structure of the alpha-Klotho/FGFR1c/FGF23 ternary complex, resolved by Chen et al. (2018) at 3.0 angstrom resolution, demonstrated that the KL2 domain of alpha-Klotho cradles FGF23 with a receptor-binding arm extending from the KL1-KL2 interdomain cleft, creating a composite binding surface for FGF23 engagement [2]. Loss of this co-receptor function produces the hyperphosphatemia, hypervitaminosis D, and ectopic calcification that characterize the kl/kl mouse phenotype and that are recapitulated in FGF23 knockout mice.

Independent of the FGF23 co-receptor function, soluble alpha-Klotho acts as a circulating endocrine factor with pleiotropic anti-aging activity. Characterized signaling activities include inhibition of the insulin/insulin-like growth factor 1 (IGF-1) pathway through suppression of receptor autophosphorylation; suppression of Wnt/beta-catenin signaling through direct binding to Wnt ligands; inhibition of transforming growth factor beta (TGF-beta) type II receptor signaling and downstream Smad phosphorylation; suppression of NF-kappaB-driven inflammatory transcription; and regulation of ion channel and transporter activity in the renal tubule, including TRPV5, TRPV6, ROMK1, and the Na+/K+-ATPase [3, 4, 5]. These FGF23-independent activities are the molecular basis for the broader anti-aging, neuroprotective, cardioprotective, and anti-fibrotic effects observed in gain-of-function and supplementation studies.

Circulating soluble alpha-Klotho levels decline with age in humans, beginning approximately in the fourth decade of life, and are markedly reduced in chronic kidney disease, where loss of renal alpha-Klotho expression precedes and contributes to the mineral and bone disorder, cardiovascular calcification, and accelerated aging phenotype of uremia [6]. Epidemiological studies have identified inverse associations between circulating soluble alpha-Klotho concentrations and all-cause mortality, cardiovascular events, and cognitive decline in community-dwelling older adults [7]. The KL-VS haplotype (defined by the F352V and C370S variants, rs9536314 and rs9527025) has been associated in some cohorts with altered klotho secretion, cortical brain volume, and cognitive resilience in aging, though replication across large cohorts remains inconsistent [8, 9].

Preclinical studies have demonstrated that recombinant alpha-Klotho protein administration, adeno-associated virus-mediated KL gene transfer, and transgenic KL overexpression produce renoprotection in ischemia-reperfusion injury and unilateral ureteral obstruction models; cardioprotection with attenuation of left ventricular hypertrophy and fibrosis; suppression of vascular calcification; and cognitive enhancement in aged, young, and alpha-synuclein transgenic mice through NMDA receptor-dependent glutamatergic mechanisms [10, 11, 12, 13]. A 2023 study in aged nonhuman primates demonstrated that a single subcutaneous injection of a klotho protein fragment enhanced spatial and working memory, representing the first primate cognitive enhancement data for the compound [14].

As of 2026, alpha-Klotho is in early clinical development. Klothea Bio launched a Phase 1b randomized, double-blind, placebo-controlled trial of AKL003, an alpha-Klotho mRNA therapeutic administered intravenously, in healthy adult volunteers in February 2026. Klotho Neurosciences is advancing KLTO-202, a KL gene therapy, toward first-in-human studies for amyotrophic lateral sclerosis. No alpha-Klotho protein or gene therapy product has received regulatory approval in any jurisdiction. Recombinant human alpha-Klotho protein is available from multiple research suppliers (R&D Systems, Abcam, Sino Biological, Thermo Fisher) for in vitro and preclinical applications. This monograph reviews the molecular identification, structural biology, receptor pharmacology, preclinical pharmacology across organ systems, the emerging clinical evidence base, sourcing and handling considerations, stack interactions, safety signal, and a comparative assessment of five anti-aging intervention candidates against alpha-Klotho on five competency standards.